WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting

Patents and Innovations

Open PDF
  • Life Sciences-Minded Strategic Patent Counseling

    Wilson Sonsini's patents and innovations attorneys have experience in global patent portfolio development and management for a variety of life sciences clients, including start-up and established biotechnology corporations, multinational pharmaceutical corporations, and premier research universities.

  • At the Cutting-Edge of Life Sciences and Technology Innovation

    Wilson Sonsini's patents and innovations professionals are responsible for developing the IP portfolios covering such inventions as CRISPR gene-editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. Our attorneys work with innovators engaged in highly technical fields, including diagnostics, genomics, bioinformatics, artificial intelligence, and materials.

  • One of the Largest Life Sciences-Focused Patent Practices in the World

    Most of Wilson Sonsini's 180-plus patent attorneys, patent agents, and IP professionals possess Ph.D.s or other advanced degrees in biology, chemistry, biomedical sciences, or engineering.

  • Substantial USPTO Experience

    Over 170 of Wilson Sonsini's attorneys and agents have been admitted to practice before the USPTO. Our team includes several former USPTO executives, including a former Administrative Patent Judge, a former Deputy Administrator in the Office of Policy and External Affairs, a former Deputy Commissioner for Patent Operations, and a former Deputy Commissioner for Patent Administration.

Life Sciences-Minded and Strategic Patent Counseling Experience

Wilson Sonsini's patents and innovations practice helps clients leverage their intellectual property, defend against claims of others, and establish a competitive position for the future in fields such as therapeutics, biologics, personalized medicine, research tools, and clean technologies. Our team helps growing companies achieve important milestones by securing, developing, and protecting their most vital IP assets, while also advising established companies responsible for advancing groundbreaking discoveries. We identify the areas in which IP protection is most critical to achieving the company's business objectives, determine the most effective methods of protection, and identify strategies to avoid issues with third-party patents.

The members of Wilson Sonsini's patents and innovations team are knowledgable in all facets of IP counseling, including the following:

  • Patent portfolio management
  • Preparation and prosecution of U.S. and foreign patent applications
  • Interference and reexamination proceedings
  • Non-infringement and validity opinions
  • Freedom-to-operate and due diligence analyses
  • Licensing and regulatory submissions
  • Litigation enforcement and defense, including USPTO trial proceedings
  • IP due diligence for initial public offerings, PIPE transactions, asset purchase agreements, and venture financings
  • FDA-related submissions and strategies such as citizen petitions and Paragraph IV certification

Key Facts About Our Practice

Wilson Sonsini's patents and innovations team is comprised of more than 180 experienced patent attorneys, patent agents, and IP professionals. In 2025, the firm had more than 770 U.S. and 2,400 foreign patents issued on behalf of clients.

At the Cutting-Edge of Life Sciences and Technology Innovation

Wilson Sonsini has an impressive track record of IP value creation, as members of our practice are responsible for the development of the IP portfolios covering such inventions as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. Our patents and innovations attorneys serve clients in the following fields:

  • Adoptive cell therapy
  • Agricultural biotechnology 
  • Animal health
  • Antibody therapeutics
  • Biochemistry
  • Bioinformatics software
  • Biomedical sciences
  • Biotechnology
  • Catalysis and oil processing
  • CAR-T cell therapies 
  • CRISPR gene editing
  • Cell therapy
  • Chemical engineering
  • Digital health
  • Diagnostics
  • Genetic engineering
  • Gene therapy
  • Genetics
  • Genome editing
  • Genomics
  • Immuno-oncology    
  • Medical devices
  • Molecular biology, RNA-based medicines
  • Nanotechnology
  • Organic and medicinal chemistry
  • Personalized medicine
  • Peptides
  • Pharmaceuticals
  • Proteomics
  • Solid state and inorganic chemistry
  • Stem cell biology
  • Small molecule therapeutics
  • Synthetic biology
  • Tissue engineering
  • Virology

One of the Largest Life Sciences-Focused Patent Practices in the World

Wilson Sonsini's patents and innovations team—which is highly integrated with the firm's corporate, litigation, and transactional practices—is comprised of more than 180 experienced patent attorneys, patent agents, and IP professionals, most of whom possess Ph.D. or other advanced degrees in such areas as biology, chemistry, immunology, biomedical sciences, engineering, or other scientific fields.

Substantial USPTO Experience

Over 170 of Wilson Sonsini's attorneys and agents have been admitted to practice before the U.S. Patent and Trademark Office. In fact, our team includes several former USPTO executives, including a former Administrative Patent Judge, a former Deputy Administrator in the Office of Policy and External Affairs, a former Deputy Commissioner for Patent Operations, and a former Deputy Commissioner for Patent Administration.

Overview

Life Sciences-Minded and Strategic Patent Counseling Experience

Wilson Sonsini's patents and innovations practice helps clients leverage their intellectual property, defend against claims of others, and establish a competitive position for the future in fields such as therapeutics, biologics, personalized medicine, research tools, and clean technologies. Our team helps growing companies achieve important milestones by securing, developing, and protecting their most vital IP assets, while also advising established companies responsible for advancing groundbreaking discoveries. We identify the areas in which IP protection is most critical to achieving the company's business objectives, determine the most effective methods of protection, and identify strategies to avoid issues with third-party patents.

The members of Wilson Sonsini's patents and innovations team are knowledgable in all facets of IP counseling, including the following:

  • Patent portfolio management
  • Preparation and prosecution of U.S. and foreign patent applications
  • Interference and reexamination proceedings
  • Non-infringement and validity opinions
  • Freedom-to-operate and due diligence analyses
  • Licensing and regulatory submissions
  • Litigation enforcement and defense, including USPTO trial proceedings
  • IP due diligence for initial public offerings, PIPE transactions, asset purchase agreements, and venture financings
  • FDA-related submissions and strategies such as citizen petitions and Paragraph IV certification

Key Facts About Our Practice

Wilson Sonsini's patents and innovations team is comprised of more than 180 experienced patent attorneys, patent agents, and IP professionals. In 2025, the firm had more than 770 U.S. and 2,400 foreign patents issued on behalf of clients.

At the Cutting-Edge of Life Sciences and Technology Innovation

Wilson Sonsini has an impressive track record of IP value creation, as members of our practice are responsible for the development of the IP portfolios covering such inventions as CRISPR gene editing, the DNA chip, cancer therapies, nanotechnology, cell-free genetic tests, medical devices, stem cell technologies, and next-generation DNA sequencing. Our patents and innovations attorneys serve clients in the following fields:

  • Adoptive cell therapy
  • Agricultural biotechnology 
  • Animal health
  • Antibody therapeutics
  • Biochemistry
  • Bioinformatics software
  • Biomedical sciences
  • Biotechnology
  • Catalysis and oil processing
  • CAR-T cell therapies 
  • CRISPR gene editing
  • Cell therapy
  • Chemical engineering
  • Digital health
  • Diagnostics
  • Genetic engineering
  • Gene therapy
  • Genetics
  • Genome editing
  • Genomics
  • Immuno-oncology    
  • Medical devices
  • Molecular biology, RNA-based medicines
  • Nanotechnology
  • Organic and medicinal chemistry
  • Personalized medicine
  • Peptides
  • Pharmaceuticals
  • Proteomics
  • Solid state and inorganic chemistry
  • Stem cell biology
  • Small molecule therapeutics
  • Synthetic biology
  • Tissue engineering
  • Virology

One of the Largest Life Sciences-Focused Patent Practices in the World

Wilson Sonsini's patents and innovations team—which is highly integrated with the firm's corporate, litigation, and transactional practices—is comprised of more than 180 experienced patent attorneys, patent agents, and IP professionals, most of whom possess Ph.D. or other advanced degrees in such areas as biology, chemistry, immunology, biomedical sciences, engineering, or other scientific fields.

Substantial USPTO Experience

Over 170 of Wilson Sonsini's attorneys and agents have been admitted to practice before the U.S. Patent and Trademark Office. In fact, our team includes several former USPTO executives, including a former Administrative Patent Judge, a former Deputy Administrator in the Office of Policy and External Affairs, a former Deputy Commissioner for Patent Operations, and a former Deputy Commissioner for Patent Administration.

Client Highlights
Wilson Sonsini Advises Prolific Machines on Patent and Trademark Matters Related to $50 Million Series B2 Financing
On October 14, 2026, Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions, announced the initial closing of its $50 million Series B2 financing led by Atoms & Bits and Nant Capital. Wilson Sonsini Goodrich & Rosati advised Prolific Machines on patent and trademark matters related to the transaction.
Client Highlights
Firm Advises Oxford Science Enterprises on IP Matters Related to Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A led by Oxford Science Enterprises (OSE) and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. Wilson Sonsini Goodrich & Rosati advised OSE on IP due diligence related to the transaction.
Client Highlights
Wilson Sonsini Advises Atrium Therapeutics on Patent Matters Related to $50 Million Private Placement
On October 8, 2026, Atrium Therapeutics, a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, announced that it has entered into a securities purchase agreement with a group of leading institutional investors for a private placement financing. The financing is expected to result in aggregate gross proceeds of approximately $50 million, before deducting placement agent fees and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Atrium Therapeutics on patent matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Universal Quantum on IP Matters Related to $100 Million Series A
On October 8, 2026, Universal Quantum, the company building large-scale quantum computing systems for real-world use, announced it has secured over $100 million in Series A funding. The round was co-led by DCVC and Firgun Ventures, with participation from EDBI, Artal (advised by Invus), Integral GlobalTech, Main Sequence, Hostplus, NGS Super, IAG Capital, EdenBase, Eigenstate Holdings, SiteGround Capital, and Dave Baszucki, as well as other existing and new strategic investors. Wilson Sonsini Goodrich & Rosati advised Universal Quantum on patent matters related to the transaction.
Wilson Sonsini Advises ADARx on IP Matters Related to IPO and Concurrent Private Placement
On September 24, 2026, ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced the pricing of its upsized initial public offering (IPO) of 26,250,000 shares of common stock at $17.00 per share. All of the shares of common stock are being offered by ADARx. The shares began trading on the Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.”
Client Highlights
Wilson Sonsini Advises Kura Oncology on Patent Matters Related to Launch of Caspian Therapeutics
On September 9, 2026, Kura Oncology (Kura), a biopharmaceutical company focused on precision medicines for the treatment of cancer, announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian was established around KO-7246, a next-generation, highly selective menin inhibitor purpose-designed for chronic metabolic diseases, together with related intellectual property and know-how contributed by Kura. Kura will retain approximately half ownership of Caspian and board representation. Caspian will operate with dedicated leadership and external capital with access to Kura’s research, development, and corporate capabilities under an intercompany services arrangement. Wilson Sonsini Goodrich & Rosati advised Kura on patent matters related to the transaction.
View All
Insights
Client Highlights
Wilson Sonsini Advises Prolific Machines on Patent and Trademark Matters Related to $50 Million Series B2 Financing
On October 14, 2026, Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions, announced the initial closing of its $50 million Series B2 financing led by Atoms & Bits and Nant Capital. Wilson Sonsini Goodrich & Rosati advised Prolific Machines on patent and trademark matters related to the transaction.
Client Highlights
Firm Advises Oxford Science Enterprises on IP Matters Related to Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A led by Oxford Science Enterprises (OSE) and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. Wilson Sonsini Goodrich & Rosati advised OSE on IP due diligence related to the transaction.
Client Highlights
Wilson Sonsini Advises Atrium Therapeutics on Patent Matters Related to $50 Million Private Placement
On October 8, 2026, Atrium Therapeutics, a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, announced that it has entered into a securities purchase agreement with a group of leading institutional investors for a private placement financing. The financing is expected to result in aggregate gross proceeds of approximately $50 million, before deducting placement agent fees and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Atrium Therapeutics on patent matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Universal Quantum on IP Matters Related to $100 Million Series A
On October 8, 2026, Universal Quantum, the company building large-scale quantum computing systems for real-world use, announced it has secured over $100 million in Series A funding. The round was co-led by DCVC and Firgun Ventures, with participation from EDBI, Artal (advised by Invus), Integral GlobalTech, Main Sequence, Hostplus, NGS Super, IAG Capital, EdenBase, Eigenstate Holdings, SiteGround Capital, and Dave Baszucki, as well as other existing and new strategic investors. Wilson Sonsini Goodrich & Rosati advised Universal Quantum on patent matters related to the transaction.
Wilson Sonsini Advises ADARx on IP Matters Related to IPO and Concurrent Private Placement
On September 24, 2026, ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced the pricing of its upsized initial public offering (IPO) of 26,250,000 shares of common stock at $17.00 per share. All of the shares of common stock are being offered by ADARx. The shares began trading on the Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.”
Client Highlights
Wilson Sonsini Advises Kura Oncology on Patent Matters Related to Launch of Caspian Therapeutics
On September 9, 2026, Kura Oncology (Kura), a biopharmaceutical company focused on precision medicines for the treatment of cancer, announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian was established around KO-7246, a next-generation, highly selective menin inhibitor purpose-designed for chronic metabolic diseases, together with related intellectual property and know-how contributed by Kura. Kura will retain approximately half ownership of Caspian and board representation. Caspian will operate with dedicated leadership and external capital with access to Kura’s research, development, and corporate capabilities under an intercompany services arrangement. Wilson Sonsini Goodrich & Rosati advised Kura on patent matters related to the transaction.
View All
Affiliated Programs
Wilson Sonsini and HBA San Francisco Bay Area Chapter Year-End Educational Networking Event
Wilson Sonsini Goodrich & Rosati is proud to sponsor the Healthcare Businesswomen’s Association (HBA).
Affiliated Programs
HBA Speaker Panel: Biotech Companies and Investors Face a Growing National Security Regulatory Thicket
Wilson Sonsini is proud to co-sponsor a Healthcare Businesswomen's Association (HBA) speaker program.
Affiliated Programs
Intellectual Property (IP) for Antibody and Related Therapeutics: Strategies, Best Practices and Case Studies
Antibody and related biologic therapeutics present unique intellectual property (IP) challenges throughout discovery, development, and commercialization. This online workshop will bring together IP attorneys and industry experts from Haynes Boone, Wilson Sonsini, Morgan Lewis, Morrison Foerster, and Amgen to discuss practical strategies, emerging legal issues, and real-world case studies. Attendees will gain insights into protecting innovation, managing IP risks, and navigating an evolving legal landscape shaped by advances in biologics and AI.
WSGR Events
Wilson Sonsini Biotech Summit 2026
We invite you to join us for Wilson Sonsini's Third Annual Biotech Summit. This dynamic, high-profile event will convene leaders from across the biotech industry, including prominent investors, CEOs, founders, key decision makers, and researchers.
Affiliated Programs
East Coast NextGen VC Forum 2026
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with Wilson Sonsini, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Affiliated Programs
EPPICON 2026 ​- Reimagining Healthy Aging: The Science, Startups and Business of Longevity
Wilson Sonsini is pleased to sponsor EPPIC Global and the EPPICon 2026 annual meeting.
View All
Events
Affiliated Programs
Wilson Sonsini and HBA San Francisco Bay Area Chapter Year-End Educational Networking Event
Wilson Sonsini Goodrich & Rosati is proud to sponsor the Healthcare Businesswomen’s Association (HBA).
Affiliated Programs
HBA Speaker Panel: Biotech Companies and Investors Face a Growing National Security Regulatory Thicket
Wilson Sonsini is proud to co-sponsor a Healthcare Businesswomen's Association (HBA) speaker program.
Affiliated Programs
Intellectual Property (IP) for Antibody and Related Therapeutics: Strategies, Best Practices and Case Studies
Antibody and related biologic therapeutics present unique intellectual property (IP) challenges throughout discovery, development, and commercialization. This online workshop will bring together IP attorneys and industry experts from Haynes Boone, Wilson Sonsini, Morgan Lewis, Morrison Foerster, and Amgen to discuss practical strategies, emerging legal issues, and real-world case studies. Attendees will gain insights into protecting innovation, managing IP risks, and navigating an evolving legal landscape shaped by advances in biologics and AI.
WSGR Events
Wilson Sonsini Biotech Summit 2026
We invite you to join us for Wilson Sonsini's Third Annual Biotech Summit. This dynamic, high-profile event will convene leaders from across the biotech industry, including prominent investors, CEOs, founders, key decision makers, and researchers.
Affiliated Programs
East Coast NextGen VC Forum 2026
LaunchBio’s NextGen VC Forum is the premier event for venture capital professionals to deepen their knowledge of the life science and biotech sectors while building meaningful connections across the industry. The forum features expert led sessions that offer practical insights into evaluating, supporting, and scaling science-backed startups. Networking is built into the program to help participants expand their reach and grow their networks. Co-created with Wilson Sonsini, the half-day forum includes a networking lunch, three interactive one-hour sessions, and a closing happy hour.
Affiliated Programs
EPPICON 2026 ​- Reimagining Healthy Aging: The Science, Startups and Business of Longevity
Wilson Sonsini is pleased to sponsor EPPIC Global and the EPPICon 2026 annual meeting.
View All
Ali R. Alemozafar
Partner
San Francisco
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
  • Patents and Innovations
View Profile
Hin Au
Partner
Palo Alto
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
  • Patents and Innovations
View Profile
U.P. Peter Eng
Partner
Palo Alto
Peter focuses on strategic patent and innovation counseling for technology start-ups.
  • Patents and Innovations
View Profile
Ingo Hardt
Partner
San Diego
Dr. Ingo Hardt is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology. He has been a registered patent agent since 2003.
  • Patents and Innovations
View Profile
Michael Hostetler
Partner
San Francisco
Based in the SOMA and San Diego offices, Mike Hostetler provides strategic IP counseling to growth enterprises in the pharmaceutical and biotechnology, and information technology industries.
  • Patents and Innovations
View Profile
Lou Lieto
Partner
Boston
Dr. Lieto focuses on patent law-related matters for clients in the life sciences industry.
  • Patents and Innovations
View Profile
Clark Y. Lin
Partner
New York

Dr. Lin practices IP law and focuses on the pharmaceutical, life sciences, and biotech fields.

  • Patents and Innovations
View Profile
Chris W. McAndrew
Partner
Boston
Chris represents life sciences clients in patent and related IP matters.
  • Patents and Innovations
View Profile
Laurie K. McNamara
Partner
San Diego
Dr. Laurie McNamara is a partner in the San Diego and San Francisco offices of Wilson Sonsini Goodrich & Rosati, where she focuses her practice on matters related to intellectual property and patent prosecution strategy for early-stage through clinical-stage therapeutics companies. She counsels clients on matters related to global patent portfolio development and strategy, non-infringement, patentability, and freedom-to-operate studies. She advises company clients in connection with major financial transactions such as collaboration agreements, venture financings, merger & acquisitions, and public offerings. In addition to company-side representation, Laurie works with top venture capital firms related to IP diligence of target companies for financings. Laurie has represented venBio, OrbiMed, Logos Capital, Venrock, Foresight Capital, Novo Holdings, Vida Ventures, Avalon BioVentures, Two Bear Capital, and Samsara BioCapital in connection with financings of target companies developing biologics therapeutic programs.
  • Patents and Innovations
View Profile
Julia L. Minitti
Partner
Palo Alto
Julia Minitti is a partner in Wilson Sonsini's patent and innovation strategies practice.
  • Patents and Innovations
View Profile
View All
People
Ali R. Alemozafar
Partner
San Francisco
Ali counsels clients on patent strategy, prosecution, and diligence for financings, M&A, and IPOs.
  • Patents and Innovations
View Profile
Hin Au
Partner
Palo Alto
Hin Au is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, where he is a member of the patents and innovations practice. Hin provides IP strategy and counseling services to clients in a wide range of technical fields, including MedTech, digital health, biotech, medical/diagnostic devices, software, robotics, autonomous vehicle technologies, and clean energy. He has assisted many clients with building their patent portfolios and securing key strategic patents. Hin has hands-on engineering industry experience, having previously worked as an R&D engineer for six years at large U.S. semiconductor corporations. A native of Singapore, Hin is also fluent in Mandarin and Cantonese.
  • Patents and Innovations
View Profile
U.P. Peter Eng
Partner
Palo Alto
Peter focuses on strategic patent and innovation counseling for technology start-ups.
  • Patents and Innovations
View Profile
Ingo Hardt
Partner
San Diego
Dr. Ingo Hardt is a partner in the San Diego office of Wilson Sonsini Goodrich & Rosati, where he assists with the preparation and prosecution of patent applications in the fields of chemistry, pharmaceuticals, and biotechnology. He has been a registered patent agent since 2003.
  • Patents and Innovations
View Profile
Michael Hostetler
Partner
San Francisco
Based in the SOMA and San Diego offices, Mike Hostetler provides strategic IP counseling to growth enterprises in the pharmaceutical and biotechnology, and information technology industries.
  • Patents and Innovations
View Profile
Lou Lieto
Partner
Boston
Dr. Lieto focuses on patent law-related matters for clients in the life sciences industry.
  • Patents and Innovations
View Profile
Clark Y. Lin
Partner
New York

Dr. Lin practices IP law and focuses on the pharmaceutical, life sciences, and biotech fields.

  • Patents and Innovations
View Profile
Chris W. McAndrew
Partner
Boston
Chris represents life sciences clients in patent and related IP matters.
  • Patents and Innovations
View Profile
Laurie K. McNamara
Partner
San Diego
Dr. Laurie McNamara is a partner in the San Diego and San Francisco offices of Wilson Sonsini Goodrich & Rosati, where she focuses her practice on matters related to intellectual property and patent prosecution strategy for early-stage through clinical-stage therapeutics companies. She counsels clients on matters related to global patent portfolio development and strategy, non-infringement, patentability, and freedom-to-operate studies. She advises company clients in connection with major financial transactions such as collaboration agreements, venture financings, merger & acquisitions, and public offerings. In addition to company-side representation, Laurie works with top venture capital firms related to IP diligence of target companies for financings. Laurie has represented venBio, OrbiMed, Logos Capital, Venrock, Foresight Capital, Novo Holdings, Vida Ventures, Avalon BioVentures, Two Bear Capital, and Samsara BioCapital in connection with financings of target companies developing biologics therapeutic programs.
  • Patents and Innovations
View Profile
Julia L. Minitti
Partner
Palo Alto
Julia Minitti is a partner in Wilson Sonsini's patent and innovation strategies practice.
  • Patents and Innovations
View Profile
View All

Wilson Sonsini offers a suite of services for life sciences clients navigating the complexities of initial public offerings (IPOs). Leveraging the scientific experience of the firm’s Patents and Innovations and Corporate practices, our team provides specialized business and technical writing services, including drafting the business section of the registration statement, preparing investor presentations, and handling other technical writing needed during the IPO process.

Uniquely, our life sciences-focused patent team consists of more than 180 legal professionals with Ph.D.s and other advanced degrees in biology, chemistry, biomedical sciences, or engineering. Our technical writing experience encompasses biopharmaceuticals, small molecule therapeutics, research tools, medical devices, genomics, bioinformatics, artificial intelligence, and materials. Because our professionals are credentialed scientists who are intimately familiar with the science at the core of the client’s business, as scientific writers, they are well positioned to draft a Form S-1 or Form F-1 business section that meets the SEC’s exacting standards for registration statements, dovetails with the client’s patent strategy, and tells a compelling and exciting story about the client’s technology, business, and value proposition to educate potential investors.

The firm has a 60-plus-year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients. This breadth of experience informs our IPO-related scientific writing and allows us to produce optimal capitalization results for our clients.

Wilson Sonsini’s IPO scientific writers are professionals in global patent portfolio development and management. They include former senior technology licensing executives at top-tier research universities and former in-house legal counsel for major life sciences companies.

The unparalleled combination of our scientific backgrounds and industry experience enables us to accelerate and streamline the IPO process by producing a business description in advance of an IPO organizational meeting, thereby allowing management to maintain its focus on operating the business.

Technical Writing and IPO Documentation

Wilson Sonsini offers a suite of services for life sciences clients navigating the complexities of initial public offerings (IPOs). Leveraging the scientific experience of the firm’s Patents and Innovations and Corporate practices, our team provides specialized business and technical writing services, including drafting the business section of the registration statement, preparing investor presentations, and handling other technical writing needed during the IPO process.

Uniquely, our life sciences-focused patent team consists of more than 180 legal professionals with Ph.D.s and other advanced degrees in biology, chemistry, biomedical sciences, or engineering. Our technical writing experience encompasses biopharmaceuticals, small molecule therapeutics, research tools, medical devices, genomics, bioinformatics, artificial intelligence, and materials. Because our professionals are credentialed scientists who are intimately familiar with the science at the core of the client’s business, as scientific writers, they are well positioned to draft a Form S-1 or Form F-1 business section that meets the SEC’s exacting standards for registration statements, dovetails with the client’s patent strategy, and tells a compelling and exciting story about the client’s technology, business, and value proposition to educate potential investors.

The firm has a 60-plus-year history of representing trailblazers in the life sciences industry—from the earliest innovators to those that are shaping the future of healthcare today. We work closely with entrepreneurs, scientists, and investors who trust Wilson Sonsini’s strategic advice to establish and realize their companies’ business objectives. We represent life sciences companies through the entire business life cycle, from formation through IPO and strategic partnerships. We often act as outside general counsel with support from our cross-functional, global life sciences team to provide coordinated and comprehensive counsel to clients. This breadth of experience informs our IPO-related scientific writing and allows us to produce optimal capitalization results for our clients.

Wilson Sonsini’s IPO scientific writers are professionals in global patent portfolio development and management. They include former senior technology licensing executives at top-tier research universities and former in-house legal counsel for major life sciences companies.

The unparalleled combination of our scientific backgrounds and industry experience enables us to accelerate and streamline the IPO process by producing a business description in advance of an IPO organizational meeting, thereby allowing management to maintain its focus on operating the business.

Related Practices
  • Intellectual Property
  • Corporate Life Sciences
  • Healthcare and FDA Regulatory
  • Life Sciences Business Advisory Practice
  • Patent Litigation
  • Post-Grant Review
  • Technology Transactions
Related Industries
  • Life Sciences
  • Biotech
  • Digital Health
  • Global Generics
  • Medical Devices
  • Animal Health
  • Artificial Intelligence and Machine Learning
Recent Insights
Client Highlights
Wilson Sonsini Advises Prolific Machines on Patent and Trademark Matters Related to $50 Million Series B2 Financing
On October 14, 2026, Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions, announced the initial closing of its $50 million Series B2 financing led by Atoms & Bits and Nant Capital. Wilson Sonsini Goodrich & Rosati advised Prolific Machines on patent and trademark matters related to the transaction.
Learn More
Client Highlights
Firm Advises Oxford Science Enterprises on IP Matters Related to Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A led by Oxford Science Enterprises (OSE) and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. Wilson Sonsini Goodrich & Rosati advised OSE on IP due diligence related to the transaction.
Learn More
View All
Recent Events
Affiliated Programs
Wilson Sonsini and HBA San Francisco Bay Area Chapter Year-End Educational Networking Event
Wilson Sonsini Goodrich & Rosati is proud to sponsor the Healthcare Businesswomen’s Association (HBA).
Learn More
Affiliated Programs
HBA Speaker Panel: Biotech Companies and Investors Face a Growing National Security Regulatory Thicket
Wilson Sonsini is proud to co-sponsor a Healthcare Businesswomen's Association (HBA) speaker program.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Cookie Settings
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.